Previous 10 | Next 10 |
Merck's $2.7B bid for ArQule is yet another example of the Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK). More news on: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Health...
LEXINGTON, Mass. , Nov. 4, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced the appointment of Rick Batycky , Ph.D., to its Board of Di...
Pulmatrix (NASDAQ: PULM ): Q3 GAAP EPS of -$0.18 beats by $0.16 . More news on: Pulmatrix, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
LEXINGTON, Mass. , Nov. 1, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) today reports its third quarter results. Q3 2019 Highlights Pulmatrix achieved clinical and business milestones which reflect the Company's progress. These milestones include the following: ...
LEXINGTON, Mass. , Sept. 18, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) today announced that the first patient has been dosed in the Phase 2 trial evaluating Pulmazole, an inhaled iSPERSE formulation of the antifungal itraconazole in development for the treatment o...
LEXINGTON, Mass. , Aug. 19, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) has received a grant from the United States Patent and Trademark Office for US Pat. No. 10376465. Granted claims cover iSPERSE formulations of the company's lead pipeline program Pulmazole. ...
Pulmatrix (NASDAQ: PULM ): Q2 GAAP EPS of -$0.41 misses by $0.02 . More news on: Pulmatrix, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
LEXINGTON, Mass. , Aug. 5, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter results. Q2 2019 Highlights Pulmatrix achieved several clinical and business milestones which reflect the Company's progress. These milestones include the f...
LEXINGTON, Mass. , July 9, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) announces today that three sites in the United States have been activated for the Phase 2 clinical investigation for Pulmazole (PUR1900) – an inhaled iSPERSE TM formulation of the anti-fun...
LEXINGTON, Mass. , May 16, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) announces today that Dr. Robert Clarke has stepped down as Chief Executive Officer. Ted Raad will immediately transition from his current role as Chief Business Officer to that of Chief Executi...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) PR Newswire Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) a...